PT1755606E - Derivados de quinazolinona úteis como antagonistas de vanilóide - Google Patents

Derivados de quinazolinona úteis como antagonistas de vanilóide Download PDF

Info

Publication number: PT1755606E
Authority: PT; Portugal
Prior art keywords: derivatives useful; quinazolinone derivatives; vanilloid antagonists; vanilloid; antagonists
Prior art date: 2004-06-08

Application number

PT05750584T

Other languages

English (en)

Inventor

T J Ritchie

A J Culshaw

C T Brain

E K Dziadulewicz

Terance Hart

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-08

Filing date

2005-06-08

Publication date

2008-01-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32696854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1755606(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-08 Application filed by Novartis Ag filed Critical Novartis Ag

2008-01-21 Publication of PT1755606E publication Critical patent/PT1755606E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cardiology (AREA)
Immunology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Cereal-Derived Products (AREA)

PT05750584T 2004-06-08 2005-06-08 Derivados de quinazolinona úteis como antagonistas de vanilóide PT1755606E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0412769.2A GB0412769D0 (en)	2004-06-08	2004-06-08	Organic compounds

Publications (1)

Publication Number	Publication Date
PT1755606E true PT1755606E (pt)	2008-01-21

Family

ID=32696854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT05750584T PT1755606E (pt)	2004-06-08	2005-06-08	Derivados de quinazolinona úteis como antagonistas de vanilóide

Country Status (29)

Country	Link
US (4)	US7960399B2 (pt)
EP (1)	EP1755606B2 (pt)
JP (2)	JP4703650B2 (pt)
KR (2)	KR101018607B1 (pt)
CN (1)	CN1956721B (pt)
AT (1)	ATE376833T1 (pt)
AU (2)	AU2005251476C1 (pt)
BR (1)	BRPI0511933B8 (pt)
CA (1)	CA2567821C (pt)
CY (1)	CY1107846T1 (pt)
DE (1)	DE602005003128T3 (pt)
DK (1)	DK1755606T4 (pt)
EC (2)	ECSP067067A (pt)
ES (1)	ES2293584T5 (pt)
GB (1)	GB0412769D0 (pt)
HR (1)	HRP20070577T4 (pt)
IL (1)	IL179532A (pt)
MA (1)	MA28685B1 (pt)
MX (1)	MXPA06014249A (pt)
NO (1)	NO338181B1 (pt)
NZ (1)	NZ551630A (pt)
PL (1)	PL1755606T5 (pt)
PT (1)	PT1755606E (pt)
RU (2)	RU2396261C2 (pt)
SG (1)	SG153811A1 (pt)
SI (1)	SI1755606T2 (pt)
TN (1)	TNSN06405A1 (pt)
WO (1)	WO2005120510A1 (pt)
ZA (1)	ZA200609634B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0412769D0 (en)	2004-06-08	2004-07-07	Novartis Ag	Organic compounds
GB0525068D0 (en) *	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
WO2008024438A2 (en)	2006-08-23	2008-02-28	Neurogen Corporation	2-phenoxy pyrimidinone analogues
EP2094704A4 (en) *	2006-11-06	2010-12-08	Neurogen Corp	CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES
JP5755879B2 (ja)	2007-07-18	2015-07-29	ノバルティスアーゲー	Ｖｒ−１アンタゴニストとｃｏｘ−２阻害剤との相乗的組合せ剤
US8915362B2 (en)	2008-10-08	2014-12-23	Ultimed, Inc.	Sharps container
US8349852B2 (en) *	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
AR080055A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011095450A1 (en)	2010-02-02	2011-08-11	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
US8546416B2 (en)	2011-05-27	2013-10-01	Novartis Ag	3-spirocyclic piperidine derivatives as ghrelin receptor agonists
SG11201405810UA (en)	2012-05-03	2014-11-27	Novartis Ag	L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US9776975B2 (en)	2013-03-05	2017-10-03	University Of Notre Dame Du Lac	Quinazolinone antibiotics
US10016425B2 (en)	2016-11-03	2018-07-10	King Saud University	Anti-ulcerative colitis compound
KR102658602B1 (ko)	2018-10-31	2024-04-19	길리애드 사이언시즈, 인코포레이티드	Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
SG11202103839UA (en)	2018-10-31	2021-05-28	Gilead Sciences Inc	Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
JP6994061B2 (ja) *	2019-02-15	2022-01-14	ノバルティスアーゲー	４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2022520410A (ja)	2019-02-15	2022-03-30	ノバルティスアーゲー	４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤
EP3923909A1 (en) *	2019-02-15	2021-12-22	Novartis AG	Methods for treating ocular surface pain
US11453681B2 (en)	2019-05-23	2022-09-27	Gilead Sciences, Inc.	Substituted eneoxindoles and uses thereof
RU2755206C1 (ru)	2020-05-20	2021-09-14	Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН)	Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
CN116419918A (zh) *	2020-08-06	2023-07-11	诺华股份有限公司	4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品
CN116456986A (zh) *	2020-11-17	2023-07-18	苏州晶云药物科技股份有限公司	一种喹唑啉酮衍生物的新晶型及其制备方法
UY39681A (es)	2021-03-26	2022-10-31	Novartis Ag	Derivados de ciclobutilo 1,3–sustituidos y sus usos
CN120112515A (zh)	2022-09-21	2025-06-06	博士伦爱尔兰有限公司	Trpv1拮抗剂的结晶多晶型形式及其制剂
KR20250030194A (ko)	2023-08-24	2025-03-05	코웨이 주식회사	출수 장치

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US95650A (en) *		1869-10-12		Improvement in machines for bending sheet-metal for cornices
US82365A (en) *		1868-09-22		thompson
US49728A (en) *		1865-09-05		Improvement
US220227A (en) *		1879-10-07		Improvement in stri klng-movements for clocks
DE239090C (pt)	1906-11-01
US2749344A (en) *	1953-01-02	1956-06-05	Burroughs Wellcome Co	Pyrimidine compounds
DE1224316B (de)	1961-03-18	1966-09-08	Beiersdorf & Co Ag P	Verfahren zur Herstellung von 2-Methyl-3-(o-aethylphenyl)-4-oxo-3, 4-dihydrochinazolin und dessen Salzen
DE1232152B (de) †	1962-06-27	1967-01-12	Heyden Chem Fab	Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten
US3515787A (en) *	1962-06-27	1970-06-02	Squibb & Sons Inc	Compositions and methods for producing a muscle relaxing effect in an animal with 2,3 - substituted - 6 - amino-4-quinazolones
GB1003802A (en) *	1963-06-04	1965-09-08	Searle & Co	Pyrimidinone derivatives
DE1280874B (de) *	1963-10-09	1968-10-24	Boehringer Sohn Ingelheim	2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US3317388A (en) *	1964-11-20	1967-05-02	Wallace & Tiernan Inc	Methods for treating pain
US3864362A (en) *	1970-05-27	1975-02-04	Chinoin Gyogyszer Es Vegyeszet	Iso flavones
BE793594A (fr)	1972-01-03	1973-07-02	Pfizer	Nouvelles 6,7-dimethoxyquinazolines utiles comme analgesiques et tranquillisants
GB1495305A (en)	1975-09-12	1977-12-14	Pfizer Ltd	3-phenyl-4-oxo-4h-benzopyran derivatives
US4501755A (en) *	1981-05-01	1985-02-26	Pennwalt Corporation	Isoflavones useful as anti-inflammatory agents
JPS59128376A (ja) *	1983-01-13	1984-07-24	Tanabe Seiyaku Co Ltd	キナゾリノン誘導体
SU1262927A1 (ru)	1985-01-09	1997-11-20	Институт физико-органической химии и углехимии АН УССР	Способ получения 6-бром-5-метилимидазо(4,5-в)пиридина
JPS62201882A (ja) *	1985-11-18	1987-09-05	Yamanouchi Pharmaceut Co Ltd	イソフラボン誘導体
JPS62193605A (ja) *	1986-02-20	1987-08-25	Toray Ind Inc	半透性複合膜の製造方法
ZA873745B (en) *	1986-06-04	1988-10-26	Daiichi Seiyaku Co	Benzopyran derivatives
US5290780A (en) *	1991-01-30	1994-03-01	American Cyanamid Co.	Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
WO1992013535A1 (en) *	1991-02-06	1992-08-20	Research Corporation Technologies, Inc.	Anticonvulsant substituted quinazolones
US5958930A (en) *	1991-04-08	1999-09-28	Duquesne University Of The Holy Ghost	Pyrrolo pyrimidine and furo pyrimidine derivatives
US5294617A (en) *	1993-04-23	1994-03-15	American Cyanamid Company	Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5284853A (en) *	1993-04-23	1994-02-08	American Cyanamid Company	Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
EP0635263A3 (en) *	1993-06-28	1995-09-27	American Cyanamid Co	Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
HUT68558A (en)	1993-07-20	1995-06-28	Chinoin Gyogyszer Es Vegyeszet	Method for preparing isoflavon derivatives
IL112235A (en)	1994-01-03	2000-06-29	Acea Pharm Inc	1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
JPH07258224A (ja)	1994-03-24	1995-10-09	Dai Ichi Seiyaku Co Ltd	二環性化合物
US5756502A (en) *	1994-08-08	1998-05-26	Warner-Lambert Company	Quinazolinone derivatives as cholyecystokinin (CCK) ligands
ES2168463T3 (es) *	1995-03-14	2002-06-16	Novartis Ag	Derivados fenilicos trisustituidos.
US5783577A (en)	1995-09-15	1998-07-21	Trega Biosciences, Inc.	Synthesis of quinazolinone libraries and derivatives thereof
WO1997028118A1 (en)	1996-02-05	1997-08-07	Hoechst Celanese Corporation	Process for preparing anthranilic acids
WO1997044041A1 (en)	1996-05-20	1997-11-27	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
FR2750862B1 (fr)	1996-07-12	1998-10-16	Dupin Jean Pierre	Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
AU6908398A (en)	1996-10-28	1998-05-22	Versicor Inc	Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
IT1289154B1 (it)	1997-01-03	1998-09-29	Chiesi Farma Spa	Derivati di isoflavone loro preparazione e loro impiego terapeutico
JPH10259176A (ja) *	1997-03-17	1998-09-29	Japan Tobacco Inc	血管新生阻害作用を有する新規アミド誘導体及びその用途
US5948775A (en)	1997-03-19	1999-09-07	American Home Products Corporation	2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
EP1009804B1 (en)	1997-08-20	2003-10-29	The Regents of the University of California	Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
EP1047711B1 (en)	1998-01-22	2003-08-20	The Regents of the University of California	Nucleic acid sequences encoding capsaicin receptors
ID26250A (id)	1998-02-25	2000-12-07	Genetics Inst	Inhibitor-inhibitor dari enzim-enzim fosfolipase
US6500853B1 (en) *	1998-02-28	2002-12-31	Genetics Institute, Llc	Inhibitors of phospholipase enzymes
ES2253208T3 (es) *	1999-02-22	2006-06-01	Pacific Corporation	Analogos de vaniloide que contienen farmacoforos de resiniferatoxina como ponentes agonistas del receptor de vaniloide y analgesicos, composiciones y utilizaciones de los mismos.
GB9920912D0 (en)	1999-09-03	1999-11-10	Indena Spa	Novel derivatives of flavones,xanthones and coumarins
WO2001070228A1 (en)	2000-03-17	2001-09-27	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
KR20030024799A (ko) *	2000-07-20	2003-03-26	뉴로젠 코포레이션	캡사이신 수용체 리간드
JP5001505B2 (ja) *	2000-08-21	2012-08-15	株式會社アモーレパシフィック	新規チオウレア誘導体およびこれを含有する薬学的組成物
FR2815033B1 (fr)	2000-10-06	2003-09-05	Negma Lab	Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique
NZ526622A (en)	2000-12-11	2006-07-28	Amgen Sf Llc	CXCR3 antagonists
RU2003130221A (ru) *	2001-03-26	2005-04-10	Новартис АГ (CH)	Сконденсированные пиридиновые производные, предназначенные для применения в качестве антагонистов ваниллоидного рецептора при лечении боли
WO2003014064A1 (en) *	2001-07-31	2003-02-20	Bayer Healthcare Ag	Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
GB0128499D0 (en)	2001-11-28	2002-01-23	Merck Sharp & Dohme	Therapeutic agents
IL147416A (en) *	2001-12-31	2008-11-26	Israel State	Combined modalities for improved cancer treatment
US7074805B2 (en) *	2002-02-20	2006-07-11	Abbott Laboratories	Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7381730B2 (en)	2002-03-15	2008-06-03	Bristol-Myers Squibb Company	3-arylquinazoline derivatives as selective estrogen receptor beta modulators
TW200401770A (en) †	2002-06-18	2004-02-01	Sankyo Co	Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
BR0312461A (pt)	2002-07-05	2005-04-26	Hoffmann La Roche	Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e métodos para tratamento e profilaxia
EP1398032A1 (en)	2002-09-10	2004-03-17	PheneX Pharmaceuticals AG	4-Oxo-quinazolines as LXR nuclear receptor binding compounds
GB0223730D0 (en) *	2002-10-11	2002-11-20	Novartis Ag	Organic compounds
EP1558260A4 (en)	2002-11-04	2006-10-25	Nps Pharma Inc	CHINAZOLINONE COMPOUNDS AS CALCILYTIC
US7705027B2 (en)	2003-02-11	2010-04-27	Vernalis (Cambridge) Limited	Isoxazole compounds as inhibitors of heat shock proteins
US20060089353A1 (en)	2003-03-06	2006-04-27	Maki Iwahashi	Indole derivative compounds and drugs containing the compounds as the active ingredient
JP2006193426A (ja)	2003-09-05	2006-07-27	Sankyo Co Ltd	置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005040112A1 (en)	2003-10-14	2005-05-06	Oxagen Limited	Compounds with pgd2 antagonist activity
JP2007511496A (ja) †	2003-11-14	2007-05-10	メルクシャープエンドドームリミテッド	バニロイド−１受容体（ｖｒ１）の機能を調節する二環式ピリミジン−４−（３ｈ）−オン類並びにその類似体及び誘導体
NZ549046A (en)	2004-02-13	2010-06-25	Banyu Pharma Co Ltd	Fused-ring 4-oxopyrimidine derivative
GB0412769D0 (en)	2004-06-08	2004-07-07	Novartis Ag	Organic compounds
GB0412768D0 (en) *	2004-06-08	2004-07-07	Novartis Ag	Organic compounds
EP1881988A1 (en)	2005-05-11	2008-01-30	MERCK SHARP & DOHME LTD.	2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
GB0525068D0 (en)	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
JP5755879B2 (ja)	2007-07-18	2015-07-29	ノバルティスアーゲー	Ｖｒ−１アンタゴニストとｃｏｘ−２阻害剤との相乗的組合せ剤
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists

2004
- 2004-06-08 GB GBGB0412769.2A patent/GB0412769D0/en not_active Ceased
2005
- 2005-06-08 EP EP05750584A patent/EP1755606B2/en not_active Expired - Lifetime
- 2005-06-08 CA CA2567821A patent/CA2567821C/en not_active Expired - Lifetime
- 2005-06-08 KR KR1020067025788A patent/KR101018607B1/ko not_active Expired - Lifetime
- 2005-06-08 CN CN200580016187.3A patent/CN1956721B/zh not_active Expired - Lifetime
- 2005-06-08 RU RU2006146632/04A patent/RU2396261C2/ru active
- 2005-06-08 NZ NZ551630A patent/NZ551630A/en not_active IP Right Cessation
- 2005-06-08 KR KR1020107019024A patent/KR20100101017A/ko not_active Ceased
- 2005-06-08 MX MXPA06014249A patent/MXPA06014249A/es active IP Right Grant
- 2005-06-08 SG SG200903909-0A patent/SG153811A1/en unknown
- 2005-06-08 RU RU2010112450/04A patent/RU2449995C2/ru active
- 2005-06-08 DE DE602005003128T patent/DE602005003128T3/de not_active Expired - Lifetime
- 2005-06-08 PT PT05750584T patent/PT1755606E/pt unknown
- 2005-06-08 AU AU2005251476A patent/AU2005251476C1/en not_active Expired
- 2005-06-08 HR HR20070577T patent/HRP20070577T4/hr unknown
- 2005-06-08 PL PL05750584T patent/PL1755606T5/pl unknown
- 2005-06-08 JP JP2007526311A patent/JP4703650B2/ja not_active Expired - Lifetime
- 2005-06-08 DK DK05750584.4T patent/DK1755606T4/da active
- 2005-06-08 WO PCT/EP2005/006253 patent/WO2005120510A1/en not_active Ceased
- 2005-06-08 AT AT05750584T patent/ATE376833T1/de active
- 2005-06-08 US US11/569,802 patent/US7960399B2/en not_active Expired - Lifetime
- 2005-06-08 ES ES05750584T patent/ES2293584T5/es not_active Expired - Lifetime
- 2005-06-08 BR BRPI0511933A patent/BRPI0511933B8/pt active IP Right Grant
- 2005-06-08 SI SI200530141T patent/SI1755606T2/sl unknown
2006
- 2006-11-20 ZA ZA200609634A patent/ZA200609634B/xx unknown
- 2006-11-23 IL IL179532A patent/IL179532A/en active IP Right Grant
- 2006-12-07 EC EC2006007067A patent/ECSP067067A/es unknown
- 2006-12-07 TN TNP2006000405A patent/TNSN06405A1/en unknown
- 2006-12-28 MA MA29565A patent/MA28685B1/fr unknown
2007
- 2007-01-08 NO NO20070122A patent/NO338181B1/no unknown
2008
- 2008-01-03 CY CY20081100014T patent/CY1107846T1/el unknown
2009
- 2009-11-06 AU AU2009233684A patent/AU2009233684A1/en not_active Abandoned
2011
- 2011-01-21 JP JP2011010997A patent/JP5400812B2/ja not_active Expired - Lifetime
- 2011-04-19 US US13/089,943 patent/US8211902B2/en not_active Expired - Lifetime
2012
- 2012-02-14 EC ECSP12007067 patent/ECSP12007067A/es unknown
- 2012-03-29 US US13/434,248 patent/US8809528B2/en not_active Expired - Lifetime
2014
- 2014-07-02 US US14/322,165 patent/US9102653B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE602005003128D1 (de)	2007-12-13
ZA200609634B (en)	2008-08-27
DK1755606T3 (da)	2008-03-03
ATE376833T1 (de)	2007-11-15
WO2005120510A1 (en)	2005-12-22
PL1755606T5 (pl)	2011-11-30
AU2005251476A1 (en)	2005-12-22
CN1956721A (zh)	2007-05-02
SI1755606T2 (sl)	2011-10-28
JP5400812B2 (ja)	2014-01-29
US9102653B2 (en)	2015-08-11
MXPA06014249A (es)	2007-02-19
DE602005003128T3 (de)	2012-02-09
US20120184571A1 (en)	2012-07-19
KR20070021244A (ko)	2007-02-22
RU2396261C2 (ru)	2010-08-10
KR20100101017A (ko)	2010-09-15
US8809528B2 (en)	2014-08-19
US20080194595A1 (en)	2008-08-14
JP2008501763A (ja)	2008-01-24
GB0412769D0 (en)	2004-07-07
PL1755606T3 (pl)	2008-03-31
US20140315932A1 (en)	2014-10-23
AU2009233684A1 (en)	2009-11-26
RU2006146632A (ru)	2008-07-20
RU2010112450A (ru)	2011-10-10
BRPI0511933A (pt)	2008-01-22
ES2293584T3 (es)	2008-03-16
CN1956721B (zh)	2015-05-13
IL179532A (en)	2012-12-31
CA2567821A1 (en)	2005-12-22
NO20070122L (no)	2007-03-01
CA2567821C (en)	2013-12-24
KR101018607B1 (ko)	2011-03-04
US8211902B2 (en)	2012-07-03
HK1105577A1 (en)	2008-02-22
SG153811A1 (en)	2009-07-29
HRP20070577T3 (hr)	2008-08-31
IL179532A0 (en)	2007-05-15
JP4703650B2 (ja)	2011-06-15
ECSP12007067A (es)	2012-03-30
JP2011105738A (ja)	2011-06-02
US20110195983A1 (en)	2011-08-11
CY1107846T1 (el)	2013-06-19
TNSN06405A1 (en)	2008-02-22
HRP20070577T4 (hr)	2011-10-31
DE602005003128T2 (de)	2008-08-07
ES2293584T5 (es)	2011-11-23
EP1755606B1 (en)	2007-10-31
EP1755606B2 (en)	2011-06-29
EP1755606A1 (en)	2007-02-28
AU2005251476B2 (en)	2009-12-03
US7960399B2 (en)	2011-06-14
MA28685B1 (fr)	2007-06-01
NZ551630A (en)	2010-08-27
ECSP067067A (es)	2007-01-26
RU2449995C2 (ru)	2012-05-10
DK1755606T4 (da)	2011-10-24
BRPI0511933B1 (pt)	2019-04-24
NO338181B1 (no)	2016-08-01
AU2005251476C1 (en)	2011-09-15
BRPI0511933B8 (pt)	2021-05-25
SI1755606T1 (sl)	2008-08-31

Publication	Publication Date	Title
NO20070122L (no)	2007-03-01	Quinazolinonderivater anvendelige som vanilloidantagonister
TW200617009A (en)	2006-06-01	Organic compounds
MXPA06012595A (es)	2007-05-09	Analogos de amino-tetrazoles y metodos de uso.
TNSN07272A1 (en)	2008-12-31	Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists
CY1116885T1 (el)	2017-04-05	Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
TW200635921A (en)	2006-10-16	Organic compounds
MXPA05011962A (es)	2006-02-02	Oxiarenos substituidos.
WO2007047646A3 (en)	2007-09-27	Substituted dihydro-isoindolones useful in treating kinase disorders
WO2006017054A3 (en)	2006-03-16	Tricyclic-heteroaryl compounds useful as kinase inhibitors
DE602005014473D1 (en)	2009-06-25	Amino-propanolderivate
WO2006047415A3 (en)	2006-07-06	FACTOR Xa COMPOUNDS
MXPA05013905A (es)	2006-02-24	Compuestos de quinazolinona sustituidos por arilamina.
ATE445593T1 (de)	2009-10-15	Acetylenderivate
TW200628153A (en)	2006-08-16	Novel compounds
MX2007001952A (es)	2007-05-09	Compuestos y composiciones utiles como inhibidores de catepsina-s.
MXPA04002640A (es)	2004-06-07	Esteres de analogos de 3-desoxi-vitamina d3.
TW200745053A (en)	2007-12-16	9-Aminocarbonylsubstituted derivatives of glycylcyclines
TNSN06410A1 (en)	2008-02-22	Pyrrolopyridine derivatives and their use as crth2 antagonists
MX2007007554A (es)	2007-07-20	Oxiarenos sustituidos.
UY29744A1 (es)	2007-03-30	Derivados de 5-piridinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapeutica.
WO2005123694A3 (en)	2006-04-13	Quinazolinone compounds for the treatment of cough
BRPI0506996A (pt)	2007-07-03	compostos orgánicos